Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Difamilast Ointment 1% in Atopic Dermatitis
NCT05571943Phase 3Completed
- Sponsor
- Acrotech Biopharma Inc
- Start
- Sep 2022
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of difamilast in atopic dermatitis (AD), sponsored by Acrotech Biopharma Inc. Primary endpoints: Incidence and severity of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) at 52 weeks and Proportion of subjects who discontinue due to an AE at 52 weeks. Started Sep 2022; status: completed.
02
Drugs
difamilast
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05571943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05571943.